MPD: List measures where strain AKR/J is an outlier

List measures where AKR/J is an outlier

Click on pulldowns below to see AKR/J means with summary statistic tooltips.
Within each pulldown, the "up" and "down" triangles indicate when this strain is an outlier.
You can also download all phenotypes for this strain and sort by Z score in Excel.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Ackert1:31	Ackert1	body size and weight	(none)	body mass index (BMI) [kg/m²] BMI 25031 6mo 12mo 20mo	inbred	32	both		N=7	2008

Ackert1:36	Ackert1	DXA	(none)	percent fat, head excluded [%] pctfat 25036 6mo 12mo 20mo	inbred	32	both		N=7	2008

Ackert1:41	Ackert1	DXA	(none)	total tissue mass, head excluded [g] TTM 25041 6mo 12mo 20mo	inbred	32	both		N=7	2008

Ackert1:51	Ackert1	DXA	(none)	weight of fat portion of body mass, head excluded [g] fatwt 25051 6mo 12mo 20mo	inbred	32	both		N=7	2008

Berndt1:10	Berndt1	ventilator	methacholine	airway resistance (H₂O pressure) [cm/mL/s] airway_res_series 34210 baseline MCh challenge (mg/mL): 1 3 10 30	inbred	37	both	9-12wks	N=8	2010

Berndt1:21	Berndt1	ventilator	methacholine	airway resistance (as % of baseline, H₂O pressure) [%] pct_res 34221 MCh challenge (mg/mL): 1 3 10 30	inbred	37	both	9-12wks	N=8	2010

Berndt2:61	Berndt2	plethysmography	methacholine	enhanced pause penh 35161 saline 5 MCh 10 MCh 20 MCh response index	inbred	29	both	9-12wks	N=8	2010

Berndt2:81	Berndt2	ventilator	methacholine	airway resistance (H₂0 pressure) [cm/mL/s] airway_res 35181 saline 1 MCh 3 MCh 10 MCh 30 MCh response index	inbred	29	both	9-12wks	N=9	2010

Boon1:11	Boon1	body weight	influenza A (H5N1) virus	change in body weight, post-infection [%] bw_change 46911 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Brown1:36	Brown1	elevated zero maze	(none)	urine puddle count [n] urination_EZM 9436	inbred	13	both	10wks	N=9	2004

Brown1:50	Brown1	open field test	(none)	total time in center square, 5 min test, day 1 [s] center_dur_d1_OFT 9450	inbred	14	both	10wks	N=13	2004

Brown2:13	Brown2	Barnes circular maze	(none)	reversal training mean errors [n] rev_err 22513 day1 day4	inbred	13	both	10-18wks	N=12	2004

Bryant1:17	Bryant1	conditioned place preference test	oxycodone	distance traveled on day 2, 30 min test [m] distance_CPP_d2 118053 group: saline oxydocone	inbred	29	both	6-13wks	N=4	2022

Bryant1:19	Bryant1	conditioned place preference test	oxycodone	distance traveled on day 4, 30 min test [m] distance_CPP_d4 118055 group: saline oxycodone	inbred	29	both	6-13wks	N=4	2022

Bryant1:27	Bryant1	conditioned place preference test	oxycodone	distance traveled on day 9, 30 min test [m] distance_CPP_d9 118063 group: saline oxycodone	inbred	29	both	6-13wks	N=4	2022

CGDpheno1:32	CGDpheno1	complete blood count	(none)	hemoglobin concentration distribution width (HDW) [g/dL] HDW 31832	inbred w/CC8	72	both	11wks	N=7	2009

Cowell1:3	Cowell1	in vitro assay	Staphylococcus aureus	log₁₀ bacterial colony count from kidney 24h post-infection (CFU/g) [log(n/g)] kidney_CFU 49003	inbred	13	f	8wks	N=6	2012

Crabbe2:3	Crabbe2	drug and metabolite quantification	diazepam	brain diazepam and metabolite concentration, <5 min post-injection, after rotarod [ng/g] brain_DZ20 15503 trial block1 trial block2	inbred	15	m	6-7wks	N=13	1998

Crabbe2:19	Crabbe2	rotarod	diazepam	latency to fall from 5 rpm rotarod, 0 min post-injection [s] fall_DZ20 15519 trial block1 trial block2	inbred	15	m	6-7wks	N=13	1998

Crabbe3:58	Crabbe3	rotarod	(none)	average latency to fall, accelerating rotarod, 20 rpm/min (ARR2), post-injection saline control minus pre-injection saline control (SALPOST - SALBASE) [s] ARR2_chg_20rpm_saline 15858	inbred	21	both	9-17wks	N=9	2003

Deschepper1:1	Deschepper1	body weight	(none)	body weight [g] bw 10401	inbred	13	both	10wks	N=10	2004

Deschepper1:15	Deschepper1	organ weights	(none)	thymus weight [mg] thymus 10415 weight normalized to bw	inbred	13	both	10wks	N=10	2004

Donahue1:4	Donahue1	DXA	(none)	weight of fat portion of body mass, head excluded [g] fat_wt 11512	inbred w/CC7	30	both	15-16wks	N=10	2002

Donahue1:5	Donahue1	DXA	(none)	total tissue mass, head excluded [g] total_wt 11514	inbred w/CC7	30	both	15-16wks	N=10	2002

Donahue1:6	Donahue1	DXA	(none)	percentage of body mass that is fat, head excluded [%] pct_fat 11515	inbred w/CC7	30	both	15-16wks	N=10	2002

Evsikova1:76	Evsikova1	intake monitoring	(none)	water intake [mL] water 24776 daily light dark	inbred	14	both	26wks	N=7	2009

Gershenfeld1:1	Gershenfeld1	tail suspension test	(none)	TST duration of immobility, effect of saline injection on control group, 6 min test [s] TST_saline 16201 before injection after injection	inbred	12	m	5-10wks	N=5	2003

Gershenfeld1:3	Gershenfeld1	tail suspension test	imipramine	TST duration of immobility, treatment group, 6 min test [s] TST_Rx 16203 baseline imipramine 30mg/kg	inbred	12	m	5-10wks	N=5	2003

Gershenfeld1:5	Gershenfeld1	tail suspension test	imipramine	TST immobility percentage, imipramine vs. saline, 6 min test [%] TST_immobility_pct 16205	inbred	12	m	5-10wks	N=5	2003

Graubert1:18	Graubert1	histopathology	ENU	lymphoid tumor frequency rate [score] lymphoid_tumor 11618 control ENU	inbred	20	both	13-68wks	N=6	2006

Graubert1:19	Graubert1	histopathology	ENU	myeloid tumor frequency rate [score] myeloid_tumor 11619 control ENU	inbred	20	both	13-68wks	N=6	2006

Harrill2:35	Harrill2	biomarker quantification	DB289	urine kidney injury molecule 1 (KIM-1) [pg] urine_KIM1 44135 control DB289 difference	inbred	33	f	6-8wks	N=4	2012

HMDPpheno1:1	HMDPpheno1	DXA	(none)	whole body bone mineral density (BMD; skull, lumbar spine, left femur excluded) [g/cm²] BMD_body 44601	HMDP w/par	96	m	16wks	N=9	2011

HMDPpheno1:3	HMDPpheno1	DXA	(none)	bone mineral density (BMD) of lumbar spine [g/cm²] BMD_spine 44603	HMDP w/par	96	m	16wks	N=9	2011

HMDPpheno4:31	HMDPpheno4	fear conditioning test	(none)	fear training activity burst to footshock, shock reactivity, day 1 [cm/s] ftr_post_act_burst 46831	HMDP w/par	94	m	10wks	N=7	2011

Jax1:4	Jax1	body weight	(none)	body weight [g] bw 3604 age (wks): 3 4 5 6 7 8 9 10	inbred	24	both	3wks	N=40	2000

Jaxpheno7:22	Jaxpheno7	observation (SHIRPA)	(none)	status of hair coat in arena (score 0-1) [score] piloerection 34922	inbred	6	m	10wks	N=8	2010

Jaxpheno7:35	Jaxpheno7	observation (SHIRPA)	(none)	ear pinna withdrawal response to sensory stimulation on horizontal wire-grid (score 0-2) [score] pinna_reflex 34935	inbred	6	m	10wks	N=8	2010

Korstanje2:1	Korstanje2	histopathology	(none)	percentage of glomeruli exhibiting mesangial matrix expansion [%] pct_MME 51001 6mo 12mo 20mo	inbred	29	m		N=6	2013

Kumar4:19	Kumar4	gait analysis	(none)	base tail keypoint speed, variance [cm/s] speed_var 114449	inbred w/CC8	62	both	10-20wks	N=19	2021

Kumar4:20	Kumar4	gait analysis	(none)	distance right hind paw keypoint travels past previous left hind paw keypoint strike, mean [cm] step_length1_mean 114450	inbred w/CC8	62	both	10-20wks	N=19	2021

Kumar4:21	Kumar4	gait analysis	(none)	distance right hind paw keypoint travels past previous left hind paw keypoint strike, median [cm] step_length1_median 114451	inbred w/CC8	62	both	10-20wks	N=19	2021

Massett1:4	Massett1	treadmill endurance test	(none)	vertical work performed during graded exercise endurance test [kg⋅m] exercise_work 46504	inbred w/CC8	34	m	8wks	N=6	2012

Maurer1:29	Maurer1	ECG	atenolol, isoproterenol	duration P-wave [ms] P_dur 33229 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:61	Maurer1	ECG	atenolol, isoproterenol	area of QTc [ms*mV] QTc_area 33261 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Mills1:5	Mills1	apoptosis assessment	(none)	early apoptotic splenocytes [%] early_apoptotic 25205 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mills1:17	Mills1	apoptosis assessment	(none)	all apoptotic splenocytes [%] all_apoptotic 25217 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mogil1:2	Mogil1	nociception assay	(none)	latency of heated hindpaw withdrawal, Hargreaves test [s] HT 2202	inbred	11	m	6-18wks	N=6	2002

Naggert1:8	Naggert1	body weight	high-fat diet	body weight [g] bw_fat8 14308	inbred w/CC7	41	both	15-17wks	N=10	2003

Naggert1:16	Naggert1	DXA	high-fat diet	total tissue mass, head excluded [g] tissuemass_fat8 14316	inbred w/CC7	41	both	15-17wks	N=10	2003

Naggert1:17	Naggert1	DXA	high-fat diet	weight of fat portion of tissue mass, head excluded [g] fatwt_fat8 14317	inbred w/CC7	41	both	15-17wks	N=10	2003

Naggert1:19	Naggert1	DXA	high-fat diet	percentage of tissue mass that is fat, head excluded [%] pctfat_fat8 14319	inbred w/CC7	41	both	15-17wks	N=10	2003

Paigen1:4	Paigen1	colony observation	(none)	age at start of diet (local parameter) [d] age 2904	inbred	41	both		N=10	2000

Paigen1:5	Paigen1	body weight	high-fat diet	body weight [g] bw 2905 start after 8wks on diet fold change	inbred	43	both	7-11wks	N=12	2000

Peters1:15	Peters1	complete blood count	(none)	large unstained cell differential (percent of total WBC) [%] LUC 6215	inbred w/CC7	43	both	10wks	N=12	2001

Petkova1:6	Petkova1	immune cell quantification	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] LYM 24206 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:11	Petkova1	immune cell quantification	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] NEUT 24211 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:61	Petkova1	immune cell quantification	(none)	CD8 T cells, central memory, as percentage of total CD8 T cells [%] CD8_mem_central 24261 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:76	Petkova1	immune cell quantification	(none)	natural killer (NK) cells, as percentage of total lymphocytes [%] NK 24276 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Project1032:115	Project1032	operant conditioning chamber	cocaine	session duration (120 min max) (intravenous self administration), cocaine [min] session_time_cocaine 111528 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10	HMDP	66	both	9-15wks	N=3	2020

Project1149:17	Project1149	None	(none)	distance_CPP_d2 distance_CPP_d2 118114 SAL OXY	inbred	29	m		N=8	2022

Project1149:19	Project1149	None	(none)	distance_CPP_d4 distance_CPP_d4 118116 SAL OXY	inbred	29	m		N=8	2022

Project1149:27	Project1149	None	(none)	distance_CPP_d9 distance_CPP_d9 118124 SAL OXY	inbred	29	m		N=8	2022

Schonfeld1:24	Schonfeld1	body weight	(none)	body weight [g] BW 32354	inbred	11	both	9-13wks	N=6	2005

Schonfeld1:25	Schonfeld1	organ weights	(none)	liver weight [g] LW 32361	inbred	11	both	9-13wks	N=6	2005

Seburn1:5	Seburn1	body weight	(none)	body weight [g] bw 9205 start end percent change	inbred	16	both	7-9wks	N=8	2001

Seburn1:37	Seburn1	intake monitoring	(none)	water intake [mL] water 9237 3 day total daily daily adj for body weight	inbred	16	both	7-9wks	N=7	2001

Tarantino2:36	Tarantino2	forced swim test	ovariectomy	percentage of time spent immobile, 6 min test [%] FST_immobility 50636 control ovariectomy	inbred	36	f	10-12wks	N=8	2016

Tordoff1:9	Tordoff1	bottle choice test	(none)	preference for KCl (potassium chloride) solutions [%] KCl_pref 6109 concentration (mM): 10 30 100 200 300	inbred	28	m	4-12wks	N=12	2001

Vulpe1:2	Vulpe1	mineral quantification	(none)	iron (Fe) content in liver, dry weight [µg/g] iron 36802	inbred	18	both	8wks	N=6	2010

Wahlsten2:1	Wahlsten2	behavior observation	(none)	number of tests with squeaks [score] nsqueak 16001	inbred	21	both	10-12wks	N=10	2003

Wahlsten2:4	Wahlsten2	behavior observation	(none)	number of placid tests, capture ratings + hold ratings [score] nplacid 16004	inbred	21	both	10-12wks	N=10	2003

Wiltshire3:76	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SCG5 (SGNE), relative fluorescence intensity SCG5 38176 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:82	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:85	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SST, relative fluorescence intensity SST 38185 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Xing1:31	Xing1	ECG	(none)	interval QT [ms] QT 24931 6mo 12mo 20mo	inbred	29	both		N=7	2008

Xing1:41	Xing1	ECG	(none)	interval ST [ms] ST 24941 6mo 12mo 20mo	inbred	29	both		N=7	2008

Xing2:4	Xing2	gait analysis	(none)	gait score (1-3) [score] gait_score 36304 6mo 12mo 18mo	inbred	31	both		N=7	2010

Yuan3:76	Yuan3	metabolic panel	(none)	thyroxine (serum T4) [µg/dL] T4 24476 6mo 12mo 18mo	inbred	32	both		N=7	2008

List measures where AKR/J is an outlier

Filter Table Results